

COST OF TREATMENT ANALYSIS OF BIOSIMILAR AND INNOVATOR INFLIXIMAB IN A TERTIARY LEVEL HOSPITAL

Mondelo García C, Fernández Bargiela N, García Queiruga M, Feal Cortizas B, Lestón Vázquez M, Giménez Arufe V, Martín Herranz I

Servicio de Farmacia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 84. 15006 A Coruña, Spain.

Background

- ❖ The availability of biosimilar infliximab (IFX) has been postulated to offer cost savings compared to innovator IFX, which could lead to patients being switched between products.

Purpose

- ❖ To analyze the demographic characteristics and pathologies of patients treated with infliximab and to evaluate the cost effectiveness of switching from innovator to biosimilar drug.

Material and methods

Observational retrospective six-month study. **Sample:** 100% patients treated with IFX.

Data sources: electronic medical records (IANUS®), pharmaceutical application (SIMON®), management application (SINFHOS®) and pharmaceutical records.

Analyzed data → number of intravenous mixtures prepared, number of patients, age, sex, weight, diagnosis, treatment received, dosage and cost of the treatment

Results

189 patients

616 prepared intravenous mixtures

70.5% innovator IFX | 29.5% biosimilar IFX



131 patients with innovator IFX

68 women (51.9%) ♀ | 63 men (48.1%) ♂

Average age: 47.3 years-old (12-83)

Average weight: 71.7 Kg (48-132)

Diagnosis	Number of patients
Crohn disease	31
Ulcerative colitis	27
Psoriatic arthritis	25
Rheumatoid arthritis	23
Ankylosing spondylitis	18
Psoriasis	2
Others	5

Doses	Number of patients
5 mg/kg	81
3 mg/kg	50

58 patients with biosimilar IFX

32 women (55.2%) ♀ | 26 men (44.8%) ♂

Average age: 42.5 years-old (8-72)

Average weight: 65.8 Kg (23-160 Kg)

Diagnosis	Number of patients
Ulcerative colitis	14
Crohn disease	11
Psoriatic arthritis	11
Rheumatoid arthritis	7
Ankylosing spondylitis	6
Psoriasis	1
Others	8

Doses	Number of patients
5 mg/kg	36
3 mg/kg	22

Drug	Expenditure (€)
Innovative drug	508,297.20
Biosimilar drug	177,923.20

Total expenditure
686,505.40 €

If all patients were treated with the biosimilar drug

Estimated annual saving
144,024 €

Conclusions

- ❖ Biosimilar drugs are a good alternative compared with innovator drugs due to the saving which can be obtained with their use.
- ❖ Doing a close follow-up of the patients treated with biosimilar IFX would be very important to evaluate long term efficacy and safety of the treatment.